CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.

<h4>Background</h4>Although CD4 T cells are crucial for defense against M.tb, it is still not clear whether the optimal response against M.tb in fact involves both CD4 and CD8 T cells. To test this, we used a new vaccine strategy that generated a strong balanced T cell response consistin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tara Elvang, Jan P Christensen, Rolf Billeskov, Truc Thi Kim Thanh Hoang, Peter Holst, Allan Randrup Thomsen, Peter Andersen, Jes Dietrich
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2009
Materias:
R
Q
Acceso en línea:https://doaj.org/article/ecc6ac10cb574f90b990bfc1e5903c8b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ecc6ac10cb574f90b990bfc1e5903c8b
record_format dspace
spelling oai:doaj.org-article:ecc6ac10cb574f90b990bfc1e5903c8b2021-11-25T06:16:12ZCD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.1932-620310.1371/journal.pone.0005139https://doaj.org/article/ecc6ac10cb574f90b990bfc1e5903c8b2009-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19357780/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Although CD4 T cells are crucial for defense against M.tb, it is still not clear whether the optimal response against M.tb in fact involves both CD4 and CD8 T cells. To test this, we used a new vaccine strategy that generated a strong balanced T cell response consisting of both CD4 and CD8 T cells.<h4>Methods and findings</h4>To compare CD4 and CD8 responses against Ag85B-TB10.4 (H4), H4 was delivered as a subunit vaccine in cationic liposomes (CAF01), expressed in Ad5 (Ad-H4) or as a heterologous prime boost vaccination. H4/CAF01 induced primarily CD4 T cells and Ad-H4 gave predominantly a CD8 T cell response. In contrast, the heterologous prime boost combination resulted in augmentation of both the CD4 and CD8 response. The majority (>40%) of the CD4 T cells induced by the heterologous prime boost protocol were polyfunctional, and expressed IFN-gamma(+), IL-2(+), and TNF-alpha(+), whereas most of the CD8 T cells expressed IFN-gamma(+) and TNF-alpha(+) and possessed strong cytotoxic potential. The heterologous prime boost protocol also gave an increase in protective efficacy against M.tb challenge compared to H4/CAF01 and Ad-H4. Both the H4 specific CD4 and CD8 T cells were recruited to the site of infection, at the onset of infection. However, compared to CD8 T cells, CD4 T cells showed more extensive recruitment and were the main T cell subset proliferating at the site of infection.<h4>Conclusions/significance</h4>Heterologous prime boost based on H4, produced an additive effect on the priming of CD4 and CD8 cells and in terms of the protective capacity of the vaccine, and therefore represent an interesting new vaccine strategy against M.tb. However, CD4 and CD8 T cells respond very differently to live M.tb challenge, in a manner which supports the consensus that CD4 T cells do play the major role during the early stages of an M.tb infection.Tara ElvangJan P ChristensenRolf BilleskovTruc Thi Kim Thanh HoangPeter HolstAllan Randrup ThomsenPeter AndersenJes DietrichPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 4, Iss 4, p e5139 (2009)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Tara Elvang
Jan P Christensen
Rolf Billeskov
Truc Thi Kim Thanh Hoang
Peter Holst
Allan Randrup Thomsen
Peter Andersen
Jes Dietrich
CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
description <h4>Background</h4>Although CD4 T cells are crucial for defense against M.tb, it is still not clear whether the optimal response against M.tb in fact involves both CD4 and CD8 T cells. To test this, we used a new vaccine strategy that generated a strong balanced T cell response consisting of both CD4 and CD8 T cells.<h4>Methods and findings</h4>To compare CD4 and CD8 responses against Ag85B-TB10.4 (H4), H4 was delivered as a subunit vaccine in cationic liposomes (CAF01), expressed in Ad5 (Ad-H4) or as a heterologous prime boost vaccination. H4/CAF01 induced primarily CD4 T cells and Ad-H4 gave predominantly a CD8 T cell response. In contrast, the heterologous prime boost combination resulted in augmentation of both the CD4 and CD8 response. The majority (>40%) of the CD4 T cells induced by the heterologous prime boost protocol were polyfunctional, and expressed IFN-gamma(+), IL-2(+), and TNF-alpha(+), whereas most of the CD8 T cells expressed IFN-gamma(+) and TNF-alpha(+) and possessed strong cytotoxic potential. The heterologous prime boost protocol also gave an increase in protective efficacy against M.tb challenge compared to H4/CAF01 and Ad-H4. Both the H4 specific CD4 and CD8 T cells were recruited to the site of infection, at the onset of infection. However, compared to CD8 T cells, CD4 T cells showed more extensive recruitment and were the main T cell subset proliferating at the site of infection.<h4>Conclusions/significance</h4>Heterologous prime boost based on H4, produced an additive effect on the priming of CD4 and CD8 cells and in terms of the protective capacity of the vaccine, and therefore represent an interesting new vaccine strategy against M.tb. However, CD4 and CD8 T cells respond very differently to live M.tb challenge, in a manner which supports the consensus that CD4 T cells do play the major role during the early stages of an M.tb infection.
format article
author Tara Elvang
Jan P Christensen
Rolf Billeskov
Truc Thi Kim Thanh Hoang
Peter Holst
Allan Randrup Thomsen
Peter Andersen
Jes Dietrich
author_facet Tara Elvang
Jan P Christensen
Rolf Billeskov
Truc Thi Kim Thanh Hoang
Peter Holst
Allan Randrup Thomsen
Peter Andersen
Jes Dietrich
author_sort Tara Elvang
title CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
title_short CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
title_full CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
title_fullStr CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
title_full_unstemmed CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
title_sort cd4 and cd8 t cell responses to the m. tuberculosis ag85b-tb10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
publisher Public Library of Science (PLoS)
publishDate 2009
url https://doaj.org/article/ecc6ac10cb574f90b990bfc1e5903c8b
work_keys_str_mv AT taraelvang cd4andcd8tcellresponsestothemtuberculosisag85btb104promotedbyadjuvantedsubunitadenovectororheterologousprimeboostvaccination
AT janpchristensen cd4andcd8tcellresponsestothemtuberculosisag85btb104promotedbyadjuvantedsubunitadenovectororheterologousprimeboostvaccination
AT rolfbilleskov cd4andcd8tcellresponsestothemtuberculosisag85btb104promotedbyadjuvantedsubunitadenovectororheterologousprimeboostvaccination
AT tructhikimthanhhoang cd4andcd8tcellresponsestothemtuberculosisag85btb104promotedbyadjuvantedsubunitadenovectororheterologousprimeboostvaccination
AT peterholst cd4andcd8tcellresponsestothemtuberculosisag85btb104promotedbyadjuvantedsubunitadenovectororheterologousprimeboostvaccination
AT allanrandrupthomsen cd4andcd8tcellresponsestothemtuberculosisag85btb104promotedbyadjuvantedsubunitadenovectororheterologousprimeboostvaccination
AT peterandersen cd4andcd8tcellresponsestothemtuberculosisag85btb104promotedbyadjuvantedsubunitadenovectororheterologousprimeboostvaccination
AT jesdietrich cd4andcd8tcellresponsestothemtuberculosisag85btb104promotedbyadjuvantedsubunitadenovectororheterologousprimeboostvaccination
_version_ 1718414017885634560